Could a Brain-Boosting pill lift depression?
NCT ID NCT06235905
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested an experimental oral drug called SPN-820 in 40 adults with major depressive disorder. The drug aims to enhance a key brain signaling pathway (mTORC1) that may help improve mood. Researchers measured changes in depression scores over time to see if the drug is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPN-820 (also called NV-5138), an oral drug that boosts a brain signaling pathway
What this could lead to
If it works, this could point toward a new oral treatment for major depression that acts quickly on brain cell signaling.
What could go wrong
This was a small, early-phase trial with only 40 people and no placebo group, so results may not be reliable or apply to everyone. Depression symptoms can also improve on their own.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Viking Clinical Research
Temecula, California, 92591, United States